SITE010-0221

SITE010 (ESP) › SITE010-0221

SITE010-0221

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2026-05-16

completed

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-31 (study day 65); relationship: not assessed

mild assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-22 (study day 56); relationship: not assessed

severe assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-03 (study day 37); relationship: NOT RELATED

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-29 (study day 2); relationship: NOT RELATED

mild assessed

Data queries

1

AE Anaemia (grade 1) for SITE010-0221 has onset 2026-06-05, 1 d before first dose on 2026-06-06. Confirm onset date or record as pre-treatment.

onset_on[Anaemia 2026-06-05] open